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Background: Bariatric surgery can be effective in weight reduction and diabetes remission in some
patients, but is expensive. The costs of bariatric surgery in patients with obesity and type 2 diabetes
mellitus (T2DM) were explored here.
Methods: Population-based retrospectively gathered data on patients with obesity and T2DM from the
Hong Kong Hospital Authority (2006–2017) were evaluated. Direct medical costs from baseline up to
60 months were calculated based on the frequency of healthcare service utilization and dispensing of
diabetes medication. Charlson Co-morbidity Index (CCI) scores and co-morbidity rates were measured
to compare changes in co-morbidities between surgically treated and control groups over 5 years.
One-to-five propensity score matching was applied.
Results: Overall, 401 eligible surgical patients were matched with 1894 non-surgical patients. Direct
medical costs were much higher for surgical than non-surgical patients in the index year (€36 752
and €5788 respectively; P < 0⋅001) mainly owing to the bariatric procedure. The 5-year cumulative
costs incurred by surgical patients were also higher (€54 135 versus €28 603; P <0⋅001). Patients who
had bariatric surgery had more visits to outpatient and allied health professionals than those who did
not across the 5-year period. Surgical patients had significantly better CCI scores than controls after
the baseline measurement (mean 3⋅82 versus 4⋅38 at 5 years; P = 0⋅016). Costs of glucose-lowering
medications were similar between two groups, except that surgical patients had significantly lower costs
of glucose-lowering medications in year 2 (€973 versus €1395; P =0.012).
Conclusion: Bariatric surgery in obese patients with T2DM is expensive, but leads to an improved
co-morbidity profile, and reduced length of hospitalization.
Paper accepted 9 July 2020
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11970
Introduction
As populations age and lifestyles change, the prevalence
of obesity and obesity-related type 2 diabetes mellitus
(T2DM) is increasing worldwide1. Since 1980, the preva-
lence of obesity has doubled in over 70 countries2, and
the global number of patients with T2DM is projected to
rise sharply from 451 million in 2017 to 693 million in
20453. The alarming increase in the prevalence of diabetes
is especially severe in Asian countries, the populations
of which are more likely to develop T2DM at a lower
BMI and a younger age than Caucasian populations4.
The economic burden of both obesity-related disorders is
exerting great pressure on healthcare systems5,6.
Although lifestyle interventions are considered as the
first-line treatment for patients with both obesity and
T2DM7, these are often limited by lack of patient
commitment8. As a consequence, bariatric surgery has
been suggested for the treatment of morbid obesity9,
and may improve T2DM and related complications in
some patients10–13. The reported unit cost of bariatric
procedures ranges from €6771 (US $7423) to €30 595 (US
$33 541), with a mean of €13 125 (US $14 389)14. However,
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the mean cost of lifestyle intervention to achieve weight
loss of 1 kg is only €49 (US $53⋅87) for 2 months (up to
€916 (US $1005⋅36) for 12 months)15. It was expected
that there would be reduced costs of prescriptions, out-
patient visits and/or hospitalization in the early years
of bariatrics16–21. However, most economic evaluations
were conducted in the USA17–19, and many healthcare
systems differ from that in the USA in terms of costs
and billing. This study aimed to estimate direct medical
costs for patients with obesity and T2DM who had under-
gone bariatric surgery and those of matched non-surgical
patients over a 5-year period.
Methods
The study design and population were described
previously22. In brief, a population-based retrospective
cohort of patients with obesity and T2DM who had ever
used public healthcare services between January 2006 and
December 2017 was assembled from the Clinical Manage-
ment System managed by Hong Kong Hospital Authority
(HA). Patients who had undergone bariatric surgery were
identified based on a predefined list of ICD-9-CM pro-
cedure codes, whereas T2DM and other co-morbidities
were identified through ICD-9-CM diagnosis codes and
International Classification of Primary Care version 2
codes (Table S1, supporting information). Surgical patients
were excluded if they underwent non-bariatric operations,
did not have pre-existing T2DM, had no BMI readings
or had a BMI reading below 27⋅5 kg/m2 at the index date
(date of bariatric surgery)23. A one-to-five propensity score
matching method was used to match each eligible surgical
patient with up to five non-surgical patients. The index
date for non-surgical patients was the same as that of their
matched surgical patients.
All procedures were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. Eth-
ical approval for this study was granted by the Institu-
tional Review Board of the University of Hong Kong /HA
Hong Kong West Cluster (UW 16-1018). Consent was not
obtained as the data were analysed anonymously.
Estimation of annual direct medical costs
The dates and frequency of the use of HA healthcare ser-
vices by patients in the surgery and matched control group
in the index year and subsequent 4 years were retrieved.
Healthcare services included visits to general outpatient
clinics, specialist outpatient clinics, accident and emer-
gency departments and allied health professionals (clinical
psychologists, dietitians, occupational therapists, physio-
therapists, and smoking counselling and cessation visits),
as well as duration of stay in a general ward, ICU, car-
diac care unit and high-dependency unit. Unit costs of
healthcare services were extracted from the public charges
to non-eligible persons listed in the 2017 Government
Gazette and HA Ordinance (Chapter 113)24. Addition-
ally, for patients having bariatric surgery, the unit costs of
bariatric and revisional procedures were estimated based on
the private charges for operations (midpoint value) listed
on the HA website25 and personal communication with
bariatric surgeons.
Data on types of antidiabetic drug prescribed and days’
supply of each antidiabetic drug dispensed at each clinic
visit during follow-up were also retrieved. Diabetes med-
ications included were: insulin, metformin, thiazolidine-
dione, dipeptidyl peptidase 4 inhibitors, sodium glucose
co-transporter 2 inhibitors and glucagon-like peptide 1
receptor agonists. Costs of diabetes medications per 30-day
supply were based on published data26, and the midpoints
of the cost range for each class of diabetes medication were
used to estimate the medication costs.
An exchange rate of €1⋅00 = HK $8⋅50 was used to con-
vert Hong Kong dollars to euros. The unit costs of health-
care services and diabetes medications are summarized in
Table S2 (supporting information).
Annual direct medical costs for each patient were calcu-
lated based on the formula:
Annual direct medical costs
=
(∑
frequency of the healthcare service use





days supply of diabetes
medication × midpoint of cost range of




Numbers of patients with various co-morbidities (hyper-
tension, mental health problems, hyperlipidaemia, obstruc-
tive sleep apnoea, gallbladder disease, musculoskeletal and
chronic orthopaedic disorders, cardiovascular disease
(CVD), severe hypoglycaemia, chronic lung disease,
chronic renal disease (CRD)) and in different Charlson
Co-morbidity Index (CCI) categories (1, 2, 3, 4 or 5
and above, or died) were measured from baseline up to
60 months. Co-morbidity rates and CCI scores over the
years were not adjusted for disease remission, owing to
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(n = 582) P‡
Sociodemographic data
Age (years)* 53(13) 53(14) 0⋅916 0⋅006§ 62(14) 61(14) 0⋅631§
Women 201 (50⋅1) 901 (47⋅6) 0⋅353 0⋅051 63 (53⋅8) 282 (48⋅5) 0⋅287
Clinical parameters*
BMI (kg/m2) 36⋅8(5⋅1) 36⋅3(6⋅1) 0⋅121§ 0⋅090 32⋅2(5⋅5) 34⋅1(5⋅5) 0⋅032§
Waist circumference (cm) 113⋅2(12⋅0) 109⋅7(12⋅7) <0⋅001§ 0⋅278 103⋅9(10⋅4) 109⋅5(12⋅4) 0⋅020§
HbA1c (%) 7⋅66(1⋅51) 7⋅56(1⋅77) 0⋅262§ 0⋅065 6⋅92(1⋅44) 7⋅45(1⋅53) 0⋅009§
Systolic BP (mmHg) 134⋅7(16⋅8) 134⋅0(16⋅7) 0⋅520§ 0⋅040 132⋅5(19⋅0) 132⋅6(16⋅3) 0⋅973§
Diastolic BP (mmHg) 77⋅5(10⋅4) 77⋅4(10⋅3) 0⋅809§ 0⋅015 74⋅2(10⋅5) 75⋅7(9⋅6) 0⋅196§
Total cholesterol (mmol/l) 4⋅31(0⋅93) 4⋅27(0⋅92) 0⋅362§ 0⋅050 4⋅43(0⋅74) 4⋅15(0⋅85) 0⋅008§
HDL-C (mmol/l) 1⋅09(0⋅29) 1⋅08(0⋅27) 0⋅536§ 0⋅033 1⋅31(0⋅35) 1⋅13(0⋅29) <0⋅001§
TC/HDL-C ratio 4⋅20(1⋅31) 4⋅14(1⋅18) 0⋅364§ 0⋅049 3⋅60(1⋅17) 3⋅88(1⋅13) 0⋅022§
LDL-C (mmol/l) 2⋅39(0⋅80) 2⋅35(0⋅75) 0⋅297§ 0⋅057 2⋅42(0⋅62) 2⋅27(0⋅71) 0⋅109§
Triglyceride (mmol/l) 1⋅88(1⋅21) 1⋅90(1⋅33) 0⋅842§ 0⋅011 1⋅58(1⋅11) 1⋅74(1⋅12) 0⋅216§
Fasting glucose (mmol/l) 8⋅01(2⋅86) 7⋅80(2⋅78) 0⋅181§ 0⋅074 6⋅85(2⋅32) 7⋅79(3⋅09) 0⋅003§
Serum creatinine (μmol/l) 84⋅3(67⋅6) 84⋅0(54⋅6) 0⋅910§ 0⋅006 93⋅8(114⋅6) 104⋅8(107⋅4) 0⋅379§
eGFR (ml per min per 1⋅73 m2) 92⋅4(31⋅0) 90⋅8(30⋅1) 0⋅359§ 0⋅050 83⋅4(28⋅3) 78⋅6(27⋅6) 0⋅003§
Co-morbidities
Duration of DM (years)* 4⋅12(3⋅14) 4⋅36(2⋅84) 0⋅136§ 0⋅079 7⋅46(2⋅09) 8⋅10(1⋅76) <0⋅001§
Insulin, ever used (%) 78 (19⋅5) 362 (19⋅1) 0⋅876 0⋅009 20 (17⋅1) 102 (17⋅5) 0⋅911
Oral antidiabetic drugs, ever used 231 (57⋅6) 1127 (59⋅5) 0⋅495 0⋅037 71 (60⋅7) 370 (63⋅6) 0⋅554
History of hypertension 319 (79⋅6) 1464 (77⋅3) 0⋅336 0⋅054 95 (81⋅2) 488 (83⋅8) 0⋅482
Antihypertensive drugs, ever used 313 (78⋅1) 1470 (77⋅6) 0⋅829 0⋅012 94 (80⋅3) 473 (81⋅3) 0⋅815
History of hyperlipidaemia 205 (51⋅1) 960 (50⋅7) 0⋅874 0⋅009 62 (53⋅0) 324 (55⋅7) 0⋅595
Lipid-lowering agents ever used 214 (53⋅4) 1059 (55⋅9) 0⋅351 0⋅051 64 (54⋅7) 329 (56⋅5) 0⋅716
History of mental health problems 21 (5⋅2) 112 (5⋅9) 0⋅598 0⋅029 13 (11⋅1) 53 (9⋅1) 0⋅499
History of obstructive sleep apnoea 220 (54⋅9) 1040 (54⋅9) 0⋅986 0⋅001 57 (48⋅7) 278 (47⋅8) 0⋅851
History of gallbladder disease 34 (8⋅5) 140 (7⋅4) 0⋅455 0⋅040 20 (17⋅1) 55 (9⋅5) 0⋅015
History of musculoskeletal and chronic orthopaedic
disorders
98 (24⋅4) 481 (25⋅4) 0⋅689 0⋅022 31 (26⋅5) 154 (26⋅5) 0⋅398
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †Standardized mean difference (SMD) below 0⋅100 indicates
balance of baseline co-variable. Hb, haemoglobin; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low-density lipoprotein
cholesterol; eGFR, estimated glomerular filtration rate; DM, diabetes mellitus. ‡χ2 test, except §independent t test.
lack of data. Trends in mean CCI changes were analysed
for both groups using tests for trends.
Statistical analysis
All statistical analyses were performed in Stata version 13.1
(StataCorp, College Station, Texas, USA). All significance
tests were two-tailed and P < 0⋅050 was considered statisti-
cally significant.
Baseline co-variables
Baseline co-variables included: age, sex, BMI, and
pre-existing complications (hypertension, mental health
problems, hyperlipidaemia, obstructive sleep apnoea, gall-
bladder disease, musculoskeletal and chronic orthopaedic
disorders, CVD and CRD).
Propensity score matching method
Multiple imputation by chained equations27 was used
to address the absence of baseline data. Haemoglobin
A1c concentration, BP and low-density lipoprotein
cholesterol level were imputed by sex, BMI, history of
co-morbidities (hypertension, mental health problems,
hyperlipidaemia, obstructive sleep apnoea, gallbladder
disease, musculoskeletal and chronic orthopaedic disor-
ders and CVD), duration of T2DM, CCI category, and use
of insulin and oral antidiabetic drugs. Model parameters
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Visits to a general outpatient clinic (GOPC) and specialist outpatient clinic (SOPC), b accident and emergency department and c allied health professionals;
nights in d general ward, e ICU, cardiac care unit (CCU) and high-dependency unit (HDU), and f general ward, ICU, CCU and HDU. Values are mean(s.d.).
P < 0⋅050 versus surgery group (t test).
were estimated from multiple imputed data and then
used to obtain multiple-imputation linear predictions by
applying Rubin’s combination rules observation-wise to
the completed-data predictions28, whereby 20 imputed
data sets were created for multiple imputations. Obtained
predictions were then used in propensity score matching.
Each patient’s propensity score was computed by mul-
tivariable logistic regression adjusting for their baseline
co-variables. The calliper criteria improved the quality of
the nearest-neighbour matching by specifying a maximum
tolerance of the propensity score distance between patients
in the surgical group and those in the control group. The
propensity score matching was performed by means of
the calipmatch command on a one-to-five basis without
replacement in Stata®.
Baseline sociodemographic and clinical parameters, and
co-morbidities of patients in both groups are presented
as frequency with percentage for categorical variables and
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1 2 3 4 5
Surgery, < 60 years
Surgery, ≥ 60 years
Control, < 60 years
Control, ≥ 60 years
Surgery, BMI < 35 kg/m2
Surgery, BMI ≥ 35 kg/m2
Control, BMI < 35 kg/m2







a  Overall b  By sex
c  By  age d  By BMI
a Overall, b by sex, c by age and d by BMI. Mean costs are shown for each year, along with mean(s.d.) cumulative costs.
mean(s.d.) for continuous variables. Independent t tests or
χ2 tests were used to assess differences in baseline charac-
teristics between the two groups. The balance of baseline
co-variables between groups after matching was measured
by means of standardized mean differences (SMDs). All
SMDs less than 0⋅100 implied optimal balance between the
two groups29.
Generalized linear models
Direct estimation of annual costs using a normal Gaussian
distribution may be problematic owing to the skewness
of the data and zero-cost issues30. Therefore, generalized
linear models (GLMs) with gamma family and log-link
were used to estimate the 5-year cumulative and annual
direct medical costs accurately. GLMs, especially the
gamma regression model, perform well in the estimation
of non-negative and positively skewed cost data31, and
the model has been used widely in analyses of medical
costs32,33. The GLM goodness of fit was tested by use of
the modified Park test34. According to this test, a model
coefficient approximating to 2 indicates that the use of the
gamma distribution in GLMs is preferred.
The mean frequency and cost of visiting different types
of healthcare service from the index year up to the fifth
year in both groups of patients was determined. Estimated
mean(s.d.) 5-year annual direct medical costs were cal-
culated overall and for subgroups according to sex, age
(less than 60 years versus 60 years and over), BMI (less
than 35 kg/m2 versus 35 kg/m2 or higher), duration of
T2DM (5 years or less versus over 5 years), CCI category
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Table 2 Differences between groups in annual direct medical costs and cumulative costs overall, and in subgroups of age, sex
and BMI
Mean annual direct medical costs (€)
Year 1 Year 2 Year 3 Year 4 Year 5 Mean cumulative costs (€)
Overall
Surgery (n= 401) 36 752 4362 4697 4096 4228 54 135
Control (n= 1894) 5788 5397 5891 6402 5124 28 603
Incremental costs 30 964 –1035 –1194 –2307 –896 25 532
P* <0⋅001 <0⋅001 0⋅039 <0⋅001 <0⋅001 <0⋅001
Sex
Men
Surgery (n= 200) 36 105 4496 5151 4345 4142 54 240
Control (n= 993) 5285 5136 4895 5875 5091 26 283
Incremental costs 30 820 –640 256 –1530 –949 27 957
P* <0⋅001 0⋅030 0⋅603 <0⋅001 <0⋅001 <0⋅001
Women
Surgery (n= 201) 37 396 4229 4245 3847 4313 54 030
Control (n= 901) 6342 5685 6989 6983 5160 31 159
Incremental costs 31 054 –1457 –2744 –3136 –847 22 871
P* <0⋅001 0⋅001 0⋅010 <0⋅001 0⋅001 <0⋅001
Age
<60 years
Surgery (n= 290) 33 760 4035 3925 3100 4149 48 970
Control (n= 1290) 5086 4822 4414 4592 5088 24 003
Incremental costs 28 675 –786 –490 –1492 –939 24 967
P* <0⋅001 0⋅001 0⋅138 <0⋅001 <0⋅001 <0⋅001
≥ 60 years
Surgery (n= 111) 44 568 5215 6714 6698 4434 67 629
Control (n= 604) 7287 6626 9045 10 268 5201 38 427
Incremental costs 37 281 –1411 –2331 –3570 –767 29 202
P* <0⋅001 0⋅037 0⋅182 0⋅001 0⋅031 <0⋅001
BMI
< 35 kg/m2
Surgery (n= 150) 38 829 4279 5607 4219 3700 56 635
Control (n= 1008) 5363 4643 5422 5445 4394 25 266
Incremental costs 33 466 –364 185 –1226 –694 31 368
P* <0⋅001 0⋅264 0⋅807 0⋅008 0⋅005 <0⋅001
≥35 kg/m2
Surgery (n= 251) 35 511 4411 4153 4022 4544 52 641
Control (n= 886) 6271 6255 6425 7491 5955 32 398
Incremental costs 29 239 –1844 –2272 –3469 –1411 20 243
P* <0⋅001 <0⋅001 0⋅009 <0⋅001 <0⋅001 <0⋅001
*t test.
(less than 4 versus 4 or more), and history of CVD
and CRD.
Results
A total of 422 patients with obesity and diabetes met the
criteria for inclusion in the surgery group. After propensity
score matching, a cohort of 2295 patients (401 surgical
patients and 1894 matched controls) were included in the
present analysis (Fig. S1, supporting information).
The baseline characteristics of the two groups were
well balanced (Table 1; Fig. S2, supporting information).
The mean BMI of surgery and control patients was 36⋅8
and 36⋅3 kg/m2 respectively (P = 0⋅121, SMD 0⋅090). The
mean age of both groups was 53 years. Of 401 surgical
patients, 299 (74⋅6 per cent) underwent laparoscopic sleeve
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Surgery, ≤ 5 years
Surgery, > 5 years
Control, ≤ 5 years
Control, > 5 years
Surgery, no CRD history
Surgery, CRD history
Control, no CRD history
Control, CRD history
Surgery, no CVD history
Surgery, CVD history
Control, no CVD history
Control, CVD history
Surgery, CCI < 4
Surgery, CCI ≥ 4
Control, CCI < 4
Control, CCI ≥ 4
a  Duration of T2DM b  By CCI category
c  By  CVD history d  By CRD history
a By duration of type 2 diabetes mellitus (T2DM), b by Charlson Co-Morbidity Index (CCI) category, c by history of cardiovascular disease (CVD) and d
by history of chronic renal disease (CRD). Values are mean(s.d.). Mean costs are shown for each year, along with mean(s.d.) cumulative costs.
gastrectomy, 74 (18⋅5 per cent) laparoscopic gastric bypass,
11 (2⋅7 per cent) laparoscopic adjustable gastric banding
and 17 (4⋅2 per cent) had laparoscopic sleeve gastrectomy
with duodenojejunal bypass.
Frequency and costs of use of healthcare services
The mean number of outpatient visits each year in both
groups was between six and ten. Surgical patients had more
visits to outpatient clinics and allied health profession-
als than non-surgical patients across the 5 years (Fig. 1).
The mean number of emergency visits per year in both
groups was less than one, and the difference was signifi-
cant only in year 2 (0⋅48 and 0⋅84 in surgery and control
groups respectively; P < 0⋅001). Patients in the bariatric
surgery group had a longer mean length of stay in hospital
wards than non-surgical patients in the index year (16⋅8
versus 4⋅4 nights; P < 0⋅001). However, surgical patients
had a shorter hospital stay than non-surgical patients in
subsequent years. For both groups, the largest compo-
nent of annual direct medical costs was inpatient services
in the first year, followed by outpatient services, allied
health professional visits and emergency visits (Fig. S3,
supporting information). Reoperation rates for surgical
patients over time are given in in Table S5 (supporting
information).
Dispensing days and costs of glucose-lowering
medications
Costs of glucose-lowering medications were similar
between two groups, except that surgical patients had
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Table 3 Differences between groups in annual direct medical costs and cumulative costs in subgroups according to co-morbidities
Mean annual direct medical costs (€)
Year 1 Year 2 Year 3 Year 4 Year 5 Mean cumulative costs (€)
Duration of T2DM
≤5 years
Surgery (n= 247) 30 375 3649 4412 3977 5099 47 512
Control (n= 1190) 4385 4137 4737 5557 5925 24 742
Incremental costs 25 990 –488 –325 –1580 –827 22 770
P* <0⋅001 0⋅005 0⋅321 <0⋅001 0⋅001 <0⋅001
>5 years
Surgery (n= 154) 46 980 5505 5154 4286 2832 64 757
Control (n= 704) 8159 7526 7841 7831 3770 35 128
Incremental costs 38 821 –2021 –2688 –3545 –938 29 629
P* <0⋅001 0⋅001 0⋅059 <0⋅001 <0⋅001 <0⋅001
CCI category
<4
Surgery (n= 220) 29 278 3460 3226 2780 3914 42 658
Control (n= 1064) 4477 4393 3755 4014 4739 21 378
Incremental costs 24 801 –932 –529 –1235 –826 21 280
P* <0⋅001 <0⋅001 0⋅017 <0⋅001 <0⋅001 <0⋅001
≥4
Surgery (n= 181) 45 837 5458 6484 5695 4610 68 084
Control (n= 830) 7469 6685 8629 9464 5617 37 864
Incremental costs 38 368 –1227 –2145 –3768 –1008 30 221
P* <0⋅001 0⋅016 0⋅084 <0⋅001 <0⋅001 <0⋅001
History of CVD
Yes
Surgery (n= 65) 69 059 8270 9938 9184 7828 104 279
Control (n= 412) 10 947 9802 12 741 13 722 8457 55 669
Incremental costs 58 112 –1531 –2804 –4538 –629 48 610
P* <0⋅001 0⋅145 0⋅311 0⋅003 0⋅283 <0⋅001
No
Surgery (n= 336) 30 502 3606 3683 3111 3531 44 434
Control (n= 1482) 4354 4173 3987 4367 4198 21 078
Incremental costs 26 149 –567 –304 –1256 –666 23 356
P* <0⋅001 <0⋅001 0⋅154 <0⋅001 <0⋅001 <0⋅001
History of CRD
Yes
Surgery (n= 9) 100 062 15 446 38 987 17 346 6678 178 521
Control (n= 48) 22 291 23 111 59 471 36 578 8827 150 278
Incremental costs 77 771 –7665 –20 484 –19 232 –2148 28 242
P* <0⋅001 0⋅173 0⋅164 0⋅016 0⋅227 0⋅924
No
Surgery (n= 392) 35 299 4107 3910 3792 4172 51 279
Control (n= 1846) 5359 4937 4498 5618 5028 25 439
Incremental costs 29 940 –829 –588 –1826 –856 25 840
P* <0⋅001 <0⋅001 <0⋅001 <0⋅001 <0⋅001 <0⋅001
T2DM, type 2 diabetes mellitus; CCI, Charlson Co-Morbidity Index; CVD, cardiovascular disease; CRD, chronic renal disease. *t test.
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Table 4 Patients with co-morbidities at baseline and during follow-up




Surgery (n = 401)
Hypertension 319 (79⋅6) 327 (81⋅5) 328 (81⋅8) 329 (82⋅0) 329 (82⋅0) 330 (82⋅3) 2⋅7
Mental health problems 21 (5⋅2) 27 (6⋅7) 29 (7⋅2) 30 (7⋅5) 30 (7⋅5) 32 (8⋅0) 2⋅7
Hyperlipidaemia 205 (51⋅1) 219 (54⋅6) 220 (54⋅9) 223 (55⋅6) 226 (56⋅4) 227 (56⋅6) 5⋅5
Obstructive sleep apnoea 220 (54⋅9) 227 (56⋅6) 230 (57⋅4) 230 (57⋅4) 232 (57⋅9) 233 (58⋅1) 3⋅2
Gallbladder disease 34 (8⋅5) 39 (9⋅7) 41 (10⋅2) 41 (10⋅2) 42 (10⋅5) 44 (11⋅0) 2⋅5
Musculoskeletal and chronic orthopaedic disorders 98 (24⋅4) 104 (25⋅9) 109 (27⋅2) 110 (27⋅4) 111 (27⋅7) 113 (28⋅2) 3⋅7
Cardiovascular disease
Acute myocardial infarction 8 (2⋅0) 9 (2⋅2) 9 (2⋅2) 10 (2⋅5) 11 (2⋅7) 11 (2⋅7) 0⋅7
Other ischaemic heart disease 29 (7⋅2) 30 (7⋅5) 31 (7⋅7) 32 (8⋅0) 33 (8⋅2) 33 (8⋅2) 1⋅0
Congestive heart failure 15 (3⋅7) 17 (4⋅2) 17 (4⋅2) 17 (4⋅2) 17 (4⋅2) 17 (4⋅2) 0⋅5
Stroke 17 (4⋅2) 18 (4⋅5) 18 (4⋅5) 20 (5⋅0) 21 (5⋅2) 23 (5⋅7) 1⋅5
Peripheral vascular disease 10 (2⋅5) 11 (2⋅7) 11 (2⋅7) 11 (2⋅7) 11 (2⋅7) 11 (2⋅7) 0⋅2
Severe hypoglycaemia 64 (16⋅0) 71 (17⋅7) 72 (18⋅0) 73 (18⋅2) 74 (18⋅5) 75 (18⋅7) 2⋅7
Chronic lung disease 12 (3⋅0) 13 (3⋅2) 14 (3⋅5) 14 (3⋅5) 14 (3⋅5) 15 (3⋅7) 0⋅7
Chronic renal disease 5 (1⋅2) 6 (1⋅5) 6 (1⋅5) 6 (1⋅5) 7 (1⋅7) 7 (1⋅7) 0⋅5
Control (n = 1894)
Hypertension 1464 (77⋅3) 1489 (78⋅6) 1520 (80⋅3) 1532 (80⋅9) 1545 (81⋅6) 1549 (81⋅8) 4⋅5
Mental health problems 112 (5⋅9) 125 (6⋅6) 131 (6⋅9) 137 (7⋅2) 139 (7⋅3) 144 (7⋅6) 1⋅7
Hyperlipidaemia 960 (50⋅7) 1014 (53⋅5) 1063 (56⋅1) 1094 (57⋅8) 1113 (58⋅8) 1120 (59⋅1) 8⋅4
Obstructive sleep apnoea 1041 (55⋅0) 1054 (55⋅6) 1063 (56⋅1) 1068 (56⋅4) 1077 (56⋅9) 1079 (57⋅0) 2⋅0
Gallbladder disease 140 (7⋅4) 145 (7⋅7) 151 (8⋅0) 153 (8⋅1) 155 (8⋅2) 156 (8⋅2) 0⋅8
Musculoskeletal and chronic orthopaedic disorders 483 (25⋅5) 519 (27⋅4) 549 (29⋅0) 585 (30⋅9) 601 (31⋅7) 620 (32⋅7) 7⋅2
Cardiovascular disease
Acute myocardial infarction 42 (2⋅2) 49 (2⋅6) 51 (2⋅7) 60 (3⋅2) 63 (3⋅3) 69 (3⋅6) 1⋅4
Other ischaemic heart disease 196 (10⋅3) 208 (11⋅0) 227 (12⋅0) 237 (12⋅5) 242 (12⋅8) 248 (13⋅1) 2⋅7
Congestive heart failure 150 (7⋅9) 165 (8⋅7) 180 (9⋅5) 197 (10⋅4) 203 (10⋅7) 207 (10⋅9) 3⋅0
Stroke 142 (7⋅5) 159 (8⋅4) 179 (9⋅5) 188 (9⋅9) 195 (10⋅3) 199 (10⋅5) 3⋅0
Peripheral vascular disease 50 (2⋅6) 56 (3⋅0) 60 (3⋅2) 65 (3⋅4) 69 (3⋅6) 69 (3⋅6) 1⋅0
Severe hypoglycaemia 260 (13⋅7) 287 (15⋅2) 310 (16⋅4) 320 (16⋅9) 328 (17⋅3) 334 (17⋅6) 3⋅9
Chronic lung disease 87 (4⋅6) 91 (4⋅8) 100 (5⋅3) 105 (5⋅5) 109 (5⋅8) 112 (5⋅9) 1⋅3
Chronic renal disease 56 (3⋅0) 70 (3⋅7) 80 (4⋅2) 94 (5⋅0) 102 (5⋅4) 106 (5⋅6) 2⋅6
Values in parentheses are percentages. Patients were assumed to have the chronic diseases listed throughout follow-up once they had been diagnosed.
Co-morbidity rates were not adjusted for disease remission and loss to follow-up.
significantly lower costs of glucose-lowering medications
in year 2 (€973 versus €1395; P = 0.012). Annual total med-
ication costs were stable for control patients, fluctuating
between €1323 and €1553 (Table S3, supporting informa-
tion). Medication costs for surgical patients dipped, but
were not eliminated in the first 2 years after surgery (€1752
in year 1 and €973 in year 2) and then increased to €1836
in year 5. Indeed, the costs of glucose-lowering medica-
tion were actually higher for surgical than non-surgical
patients in years 1 and 5 (not significantly different),
although the amount of insulin prescribed decreased
after operation.
Estimated annual and cumulative direct medical
costs
The coefficients of the GLMs constructed for predicting
medical costs in each year were 1⋅43, 1⋅90, 1⋅94, 2⋅11 and
1⋅88, indicating that the use of GLMs with gamma family
and log-link in the data set were generally supported. The
impact of baseline covariates on annual medical costs are
listed in Table S6 (supporting information).
Surgical patients incurred greater medical costs than
control patients in the year before the index year (€6832
versus €5228, P = 0⋅046) (Table S7, supporting informa-
tion). Surgical patients incurred greater medical costs
than control patients in the year before the index year
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CCI, Charlson Co-morbidity Index.
(€6832 versus €5228, P = 0⋅046) (Table S7, supporting
information). Annual and cumulative direct medical
costs overall and in various subgroups are summarized
in Figs 2 and 3, and differences between the treatment
groups are shown in Tables 2 and 3. Overall, the mean(s.d.)
direct medical cost for the bariatric surgery group in
the year of surgery was €36 752(22 448), nearly seven
times that in the matched control group (€5788(4692))
(P < 0⋅001). In subsequent years, medical costs ranged from
€4096(3770) to €4697(6468) in surgical patients compared
with €5124(3324) to €6402(7181) in non-surgical patients.
In the 4-year postoperative follow-up, annual costs for
surgical patients were significantly lower than those for
their non-surgical counterparts (all P < 0⋅050). Over the
5-year follow-up, cumulative costs of €54 135(35 746) and
€28 603(28 363) were incurred by surgical and non-surgical
patients respectively (P < 0⋅001).
Similarly, surgical patients had significantly higher cumu-
lative medical costs in all subgroups, except for those
with pre-existing CRD. Patients in poorer health (such as
older patients, those with longer duration of T2DM, more
co-morbidities, and presence of CVD and CRD) incurred
greater medical costs than their counterparts who were in
better health. Of note, cumulative medical costs of surgical
patients with a history of CRD exceeded €170 000 over the
5 years, ranking the highest among all subgroups.
Changes in co-morbidity profiles
Table 4 shows rates of various co-morbidities over the
years. Over the 60 months, a smaller percentage of surgical
patients newly developed hypertension, hyperlipidaemia,
musculoskeletal and chronic orthopaedic disorders, CVD,
severe hypoglycaemia, chronic lung disease and CRD.
Mean CCI score in both groups from baseline to 60 months
is shown in Fig. S4 (supporting information). Mean CCI
score was similar in the two groups, but surgical patients
had significantly lower scores than controls in subsequent
years (3⋅82 versus 4⋅38 respectively in year 5; P = 0⋅016).
Although the mean value in the surgery group increased
from 3⋅40 to 3⋅82, the P for trend was 0⋅443, indicating that
the CCI score was stable among surgical patients. In con-
trast, P for trend in the control patients was less than 0⋅001.
The percentage of patients in low CCI categories
decreased, as patients proceeded towards high CCI cate-
gories or died in each year (Fig. 4). More surgical patients
died at 12 months, but thereafter patients in this group
seemed to proceed more slowly to CCI category at least
5 or death than non-surgical patients. Over half of deaths
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among surgical patients in the first 12 months after surgery
were due to cancer and none to bariatric surgery. Causes
of death for both groups over the years are summarized in
Table S4 (supporting information).
Discussion
The findings of this study have provided additional infor-
mation on the medical costs of bariatric surgery in an
Asian context in patients with obesity and T2DM. Surgi-
cal patients had significantly higher medical costs overall.
The inpatient costs for surgical patients were significant in
the year of surgery, but were a little lower than those of
control patients in subsequent years. Other studies18,19,35,36
reported higher inpatient costs after bariatric surgery, with
annual costs broadly similar thereafter.
Previous studies17,20,36–38 suggested that the amount of
diabetes medication per patient dropped after bariatric
surgery. The present results, however, showed a U-shape
curve for the costs of diabetes drugs in patients who had
undergone bariatric surgery, with disappointingly persis-
tent or recurrent diabetes. Cumulative costs for surgical
and non-surgical patients are expected to converge 22 years
after surgery if other conditions remain unchanged. This
is consistent with the finding of a systematic review39 that
bariatric surgery raised the total medical costs in the short
to medium term but might be cost-saving in the long term.
Of note, the relative differences (ratio between 5-year
cumulative costs of surgery and control patients) in
5-year cumulative costs between surgical and non-surgical
patients were smaller in subgroups of patients who had a
BMI of 35 kg/m2 or more, a CCI score of 4 or higher, or
history of CVD or CRD. These results implied that there
may be a shorter time to break even in these subgroups,
and so bariatric surgery was suggested more for patients
with obesity and T2DM with such features. Notably,
among patients with CRD, patients in the surgery group
had similar 5-year cumulative medical costs to those in the
control group. One possible explanation is that bariatric
surgery has renal protective effects, even in patients with
established renal diseases40–44. Improved renal function
after bariatric surgery largely reduced the annual medical
costs of surgical patients in the postoperative years.
Some limitations should be acknowledged, including
that one-to five matching is less common than one-to-one
propensity score matching. It increases precision in
cohort studies at only a small cost of bias45. Patients
treated between 2006 and 2017 were included, but those
whose index year was 2014 or later have not yet com-
pleted 5-year follow-up so costs for these patients were
extrapolated. In particular, bariatric surgery had protective
effects against hypertension, hyperlipidaemia, musculo-
skeletal and chronic orthopaedic disorders, CVD, severe
hypoglycaemia, chronic lung disease and CRD.
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Direct medical costs and changes in co-morbidities up to 5 years after bariatric surgery were measured among patients with obesity and type
2 diabetes mellitus. Although surgical patients incurred significantly greater medical costs in the index year and 5-year cumulative costs than
non-surgical patients, they had an improved co-morbidity profile.
